← Retour à la une
États-Unis · Plateformes & données · Yahoo Finance

Tsingke Highlights How Biotech Teams Can Evaluate and Advance Antibody Candidates at PEGS Europe 2026

Publié par Yahoo Finance · États-Unis il y a 9 h
Tsingke’s Business Development Manager Yuan Wu speaking with industry experts at PEGS Europe 2026.
Tsingke’s Business Development Manager Yuan Wu speaking with industry experts at PEGS Europe 2026. · Yahoo Finance

Résumé détaillé

An antibody that binds its target is a starting point for drug discovery. R&D teams still need to determine which candidates can be produced for follow-up studies, which retain the desired binding properties in the intended format, and which merit further investment.

From early antibody hits to engineered formats and antibody–oligonucleotide conjugates, Tsingke helps R&D teams generate the data they need to make the next development decision.

LISBON, Portugal, Nov. 20, 2026 /PRNewswire/ -- An antibody that binds its target is a starting point for drug discovery. R&D teams still need to determine which candidates can be produced for follow-up studies, which retain the desired binding properties in the intended format, and which merit further investment. At PEGS Europe 2026 in Lisbon, Tsingke highlighted how pharmaceutical and biotechnology teams can address these questions through an integrated workflow spanning antibody discovery, recombinant expression, engineering and characterization.

Teams starting with an immune sample or existing hybridoma clones may need to turn a list of hits into a set of recombinant antibodies they can compare. Tsingke's single B-cell screening workflow preserves native heavy- and light-chain pairing, while hybridoma sequencing gives teams a route to recover sequences from existing clones. Once candidates are expressed, teams can compare binding using assays selected for the project, such as cell-based binding by flow cytometry or binding kinetics measured by BLI or SPR. These data help teams prioritize candidates for follow-up testing.

When a program moves an antibody into a different format, such as a Fab or scFv, the team needs to know whether the reformatted molecule still meets its binding criteria. Teams can use recombinant expression and binding characterization to compare formats before committing to more extensive studies. For programs that require different binding behavior at different pH values, Tsingke also supports pH-dependent screening and engineering, with characterization tailored to the program's objectives.

What does the team need to know before testing an antibody–oligonucleotide conjugate?

For teams evaluating an antibody–oligonucleotide conjugate (AOC), the next decision often…

"Teams…

Début de l'article, extrait de Yahoo Finance. Pour lire la suite, ouvrez l'article chez le média.

Lire l'article complet sur Yahoo Finance Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (finance.yahoo.com)

À lire aussi